Mylan, Two India Drug Makers Said Bidding For Bafna Pharma
This article was originally published in PharmAsia News
Executive Summary
Bafna Pharmaceuticals reportedly is the target of two other India drug makers and U.S. based Mylan, seeking its generics and its Raricap hemoglobin drug that Bafna bought from Johnson & Johnson in 2011.